Akero Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the "Merger Agreement"), dated October 9, 2025, by and among Akero Therapeutics, Inc., a Delaware corporation ("Akero"), Novo Nordisk A/S, a Danish aktieselskab ("Parent"), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Parent ("Merger Sub"), including the form of contingent value rights agreement (the "CVR Agreement") to be entered into at or immediately prior to the effective time of the Merger by a direct or indirect wholly owned subsidiary of Parent designated in the CVR Agreement, a rights agent selected by Parent and reasonably acceptable to Akero and, solely with respect to Section 6.11 of the CVR Agreement, Parent, subject to changes permitted by the Merger Agreement, pursuant to which Merger Sub will merge with and into Akero (the "Merger"), and Akero will become a direct or indirect wholly owned subsidiary of Parent.

Akero Therapeutics, Inc.’s own tally for this item (“1. The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent, and NN ”): 66,887,600 for, 91,361 against — passed, per its Form 8-K filed December 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent, and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholl…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 17,308,580 for, 70,867 against.

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE ADOPTION OF THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.

The 75 asset managers below reported 15,432,744 for, 1,941,206 against, 5,496 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

Description as filed by funds: To approve, on an advisory, non- binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.

Akero Therapeutics, Inc.’s own tally for this item (“2. The Compensation Proposal To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by the Company to its named executive officers in connection with the Mer”): 65,621,066 for, 1,316,708 against — passed, per its Form 8-K filed December 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The following advisory votes were cast at the Special Meeting (in person or by proxy) and the non-binding proposal was approved:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 73 managers: 16,851,972 for, 305,354 against, 151,105 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 213 managers: 54,385,647 for, 1,073,930 against, 14 abstained, 11,353 not voted. Showing the 25 largest; see all in the interactive database.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 1 managers: 21,926 against.

Institutional-manager reports, all 4 managers: 290 for, 410 against.